Contract facts
FederalNo full NAICS 325412 intel page yet. Browse NAICS intelligence
Various Radiopharmaceuticals Dec Mod is a federal award for 249-Network Contract Office 9 (36C249) held by Telix Pharmaceuticals (Us) Inc. Estimated value $858K ($848K obligated). Current period of performance ends Sep 30, 2026 (potential Sep 30, 2028). Place of performance: FISHERS IN.
Various radiopharmaceuticals dec mod. Latest action is a modification.
Recompete timing
PublicCurrent PoP ended Sep 30, 2026 (17 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.
Want the durability read on 36C24926N0017? One Pursuit Analysis, $500, inside 48 business hours.
- 48 business hours
- $500
- Credits toward the Pack
Incumbent footprint
Public recordTelix Pharmaceuticals (Us) Inc — $6.9M obligated across 17 awards (firm-wide, all agencies).
Related awards
Same parent · incumbentQuery this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract 36C24926N0017?
36C24926N0017 (Various radiopharmaceuticals dec mod) is a 249-Network Contract Office 9 (36C249) award with a potential value of $858K, currently held by Telix Pharmaceuticals (Us) Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
What is 36C249-26-N-0017?
36C249-26-N-0017 is the dashed form of PIID 36C24926N0017 (Various radiopharmaceuticals dec mod), held by Telix Pharmaceuticals (Us) Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.
Which office awarded 36C24926N0017?
249-Network Contract Office 9 (36C249) awarded 36C24926N0017 to Telix Pharmaceuticals (Us) Inc (potential $858K).
Who is the incumbent on 36C24926N0017?
Telix Pharmaceuticals (Us) Inc is the incumbent with $6.9M across 17 related awards in SCOUT’s public footprint. The current period of performance ends Sep 30, 2026.
When does Telix Pharmaceuticals (Us) Inc’s 36C24926N0017 come up for recompete?
SCOUT tracks a period-of-performance end of Sep 30, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Want the durability read on 36C24926N0017? One Pursuit Analysis, $500, inside 48 business hours.
One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.
No card · under a minute · then the Sprint menu
Use SCOUT in your AI client — $29/moClassify + search inside Claude, ChatGPT, Cursor
Compare plansData: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.